Updating results

Lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care (DG35)

Evidence-based recommendations on lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care

Diagnostics guidance Published May 2019

Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA579)

Evidence-based recommendations on abemaciclib (Verzenios) for treating hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer

Technology appraisal guidance Published May 2019

Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation (TA578)

Evidence-based recommendations on durvalumab (Imfinzi) for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation

Technology appraisal guidance Published May 2019

Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)

Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive cutaneous T-cell lymphoma in adults

Technology appraisal guidance Published April 2019

Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)

Evidence-based recommendations on tildrakizumab (Ilumetri) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published April 2019

Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)

Evidence-based recommendations on certolizumab pegol (Cimzia) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published April 2019

Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) (TA576)

NICE is unable to make a recommendation about the use in the NHS of bosutinib for untreated chronic myeloid leukaemia because no evidence submission was

Technology appraisal guidance Published April 2019

Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA573)

Evidence-based recommendations on daratumumab (Darzalex) with bortezomib and dexamethasone for previously treated multiple myeloma in adults

Technology appraisal guidance Published April 2019

Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)

Evidence-based recommendations on ertugliflozin (Steglatro) as monotherapy or with metformin for treating type 2 diabetes in adults

Technology appraisal guidance Published March 2019

Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (TA571)

Evidence-based recommendations on brigatinib (Alunbrig) for treating ALK-positive advanced non-small-cell lung cancer in adults who have already had crizotinib

Technology appraisal guidance Published March 2019

Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) (TA570)

NICE is unable to make a recommendation about the use in the NHS of pembrolizumab (Keytruda) for treating recurrent or metastatic squamous cell carcinoma of the

Technology appraisal guidance Published March 2019

Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)

Evidence-based recommendations on pertuzumab (Perjeta) for adjuvant treatment (with trastuzumab and chemotherapy) of HER2-positive early stage breast cancer

Technology appraisal guidance Published March 2019

Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) (TA568)

NICE is unable to make a recommendation on abatacept (Orencia) for treating psoriatic arthritis after DMARDs in adults because of no evidence submission from

Technology appraisal guidance Published March 2019

Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (TA567)

Evidence-based recommendations on tisagenlecleucel therapy (Kymriah) for treating relapsed or refractory diffuse large B-cell lymphoma in adults

Technology appraisal guidance Published March 2019

Cochlear implants for children and adults with severe to profound deafness (TA566)

Evidence-based recommendations on cochlear implants for children and adults with severe to profound deafness

Technology appraisal guidance Published March 2019

Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal) (TA564)

NICE is unable to make a recommendation about the use in the NHS of dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive

Technology appraisal guidance Published February 2019

Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA563)

Evidence-based recommendations on abemaciclib (Verzenios) for treating locally advanced or metastatic, hormone receptor-positive, human epidermal growth factor

Technology appraisal guidance Published February 2019

Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma (TA562)

Evidence-based recommendations on encorafenib (Braftovi) with binimetinib (Mektovi) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma

Technology appraisal guidance Published February 2019

Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)

Evidence-based recommendations on venetoclax (Venclyxto) with rituximab for previously treated chronic lymphocytic leukaemia in adults

Technology appraisal guidance Published February 2019

Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) (TA560)

NICE is unable to make a recommendation about the use in the NHS of bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence

Technology appraisal guidance Published February 2019